Integra Therapeutics has developed the FiCAT gene-writing platform to develop cell therapies for autoimmune and oncology diseases and gene therapies for rare diseases. The company recently announced a...
Read moreIBEC spin-off Nanobots Therapeutics has been selected in the AECC’s 2024 call for IMPACTO grants. This is an initiative of the Spanish Association Against Cancer (AECC) aimed at technology-based mic...
Read moreTwo researchers at the Centre for Genomic Regulation (CRG) in Barcelona are tackling an urgent question: how can we stop cancer before it spreads? Thanks to new grants from the Spanish Association Aga...
Read moreIt is part of the PROFIT Project (Personalizing the Approach to Frail Oncology Patients through Assessment and Individualized Intervention), an innovative initiative focused on providing comprehensive...
Read moreDoctors Lluís Espinosa, Jenniffer Linares, and Clara Montagut lead the selected projects. Dr. Sònia Servitja participates in a study led by the IRB.
Read moreA study from IRB Barcelona, funded by Fundación CRIS contra el cáncer, demonstrates that the “previous state” of blood stem cells plays a decisive role in the subtype of leukaemia that develops....
Read moreADCE-T02 is a potential first-in-class Topoisomerase I inhibitor-based antibody-drug conjugate (ADC) targeting tissue factor, a validated ADC target overexpressed in multiple solid tumors
Read moreEl estudio, publicado en la European Journal of Pharmaceutical Sciences, propone el uso de un hidrogel biodegradable que se coloca en la cavidad dejada por el tumor tras la cirugía. Este material lib...
Read moreA study describes the development of urea-powered nanomotors that improve immunotherapy for bladder cancer. The nanomotors activate the immune system more efficiently and exceed the efficacy of curren...
Read moreAt ABYLABEL, they are commited to excellence and social responsability. This is why they are proud to present their AbyPanels, a tool that saves time and modey in the development of antibodies for res...
Read moreOryzon Genomics, S.A, a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the fou...
Read moreEl Hospital público Universitario 12 de Octubre de la Comunidad de Madrid lidera un ensayo clínico en adolescentes con cáncer para estudiar los resultados de una intervención basada en ejercicio f...
Read more